Corlanor for POTS Treatment

Postural Orthostatic Tachycardia Syndrome (POTS) is a chronic condition that can profoundly impact quality of life, causing symptoms like dizziness, rapid heart rate upon standing, fatigue, and brain fog. For many patients, these symptoms make daily activities difficult and often debilitating. Corlanor (ivabradine), initially developed to treat heart failure and angina, has emerged as a promising off-label option for managing POTS symptoms. Below, we explore how Corlanor works, its benefits, the research behind it, and what you need to know before considering it as a treatment option.

What Is Corlanor (Ivabradine)?

Corlanor, marketed as Procoralan in some countries, is a unique medication that specifically targets the sinoatrial (SA) node, the heart’s natural pacemaker. By inhibiting the "funny current" (If), Corlanor slows the heart rate without reducing blood pressure or the heart’s pumping ability. Unlike beta-blockers, which affect multiple aspects of cardiovascular function, Corlanor offers a more selective mechanism of action. This makes it particularly beneficial for POTS patients, where elevated heart rate (rather than blood pressure abnormalities) is often the central issue.

How Corlanor Helps POTS Patients

POTS is characterized by an abnormal increase in heart rate of at least 30 beats per minute (bpm) upon standing, accompanied by symptoms like dizziness, fatigue, and lightheadedness. Corlanor addresses these symptoms by:

• Reducing Heart Rate: Clinical studies show that Corlanor effectively slows heart rate, alleviating many of the symptoms associated with POTS.
• Preserving Blood Pressure Stability: Unlike beta-blockers, Corlanor does not lower blood pressure, which can be especially problematic for POTS patients.
• Improving Energy and Functionality: By lowering heart rate and reducing cardiovascular strain, patients often experience better exercise tolerance and improved daily energy levels.

Corlanor and POTS: A Brief History

Corlanor (ivabradine) was first approved by the FDA in 2015 for treating chronic heart failure in patients with reduced ejection fraction and elevated resting heart rates. Unlike traditional beta-blockers, Corlanor offered a unique mechanism by slowing the heart rate without affecting blood pressure or cardiac output, reducing hospitalization rates in heart failure patients.

Physicians began prescribing Corlanor off-label for POTS after observing its ability to manage the hallmark symptom of elevated heart rate without causing excessive fatigue or blood pressure drops seen with other treatments. Reports from specialists like Dr. Blair Grubb highlight a 75% success rate among POTS patients, with additional benefits noted in long COVID-related POTS cases. Despite its high cost in the U.S., Corlanor has gained recognition as a valuable option for patients unresponsive to traditional therapies, offering hope for improved symptom management and quality of life.

Hyperadrenergic POTS and Corlanor

One of the key subtypes of POTS is hyperadrenergic POTS, characterized by elevated norepinephrine levels when standing. This subtype often presents with symptoms like tremors, excessive sweating, and anxiety, in addition to a rapid heart rate. Corlanor has shown particular promise for patients with this subtype due to its ability to lower heart rate without triggering side effects like fatigue or hypotension.

A randomized controlled trial specifically investigating hyperadrenergic POTS found that Corlanor significantly reduced standing heart rate by approximately 17 bpm compared to placebo. Patients also experienced measurable improvements in physical and social functioning as assessed by the SF-36 Quality of Life questionnaire. Additionally, trends toward reduced norepinephrine levels suggest that Corlanor may help down-regulate sympathetic nervous system activity, further alleviating symptoms.

Research Supporting Corlanor’s Use in POTS and Long COVID

Although Corlanor is not FDA-approved for POTS, its off-label use is supported by a growing body of evidence:

• Small Clinical Trials: Studies have demonstrated Corlanor’s effectiveness in reducing heart rate during tilt-table tests, a standard diagnostic tool for POTS. Patients reported improvements in symptoms like dizziness and palpitations.
• Adolescent Studies: A retrospective analysis found that nearly 70% of adolescents with POTS experienced significant symptom relief while using Corlanor, including improved heart rate control and reduced fatigue.
• Long COVID Cases: In patients with POTS-like symptoms linked to long COVID, Corlanor improved heart rate, exercise tolerance, and energy levels in preliminary observations.
• Hyperadrenergic POTS: In addition to lowering heart rate, Corlanor may reduce norepinephrine levels, helping to manage this specific POTS subtype.
• Comparison to Beta-Blockers: Corlanor offers comparable heart rate-lowering benefits to beta-blockers but with fewer side effects, such as fatigue and blood pressure drops.
• Combination Therapies: Corlanor has been used in conjunction with medications like midodrine or fludrocortisone for patients with more complex POTS symptoms, offering additional flexibility in treatment.

Why Corlanor Stands Out

Many POTS patients face challenges with traditional treatments like beta-blockers or midodrine due to side effects such as excessive fatigue, dizziness, or blood pressure drops. Corlanor offers several advantages:

• Selective Action: By targeting the heart rate specifically, Corlanor avoids broader cardiovascular side effects.
• Better Tolerability: Patients report fewer side effects compared to traditional medications, making it a safer option for sensitive individuals.
• Versatility: Corlanor is not only effective for traditional POTS but also for managing related conditions like vasovagal syncope and POTS-like symptoms in long COVID cases.

Dosage and Administration

Corlanor is prescribed off-label for POTS, typically starting with a low dose, such as 2.5 mg twice daily. The dose can be adjusted based on individual response and tolerability. It is critical to work closely with a healthcare provider experienced in managing POTS to monitor your progress and ensure the treatment is effective and safe.

Potential Side Effects of Corlanor

Corlanor is generally well-tolerated, but like any medication, it can cause side effects. Common ones include:

• Visual Phenomena (Phosphenes): Temporary sensations of enhanced brightness in the visual field, which often resolve with continued use or discontinuation.
• Mild Bradycardia: Slower-than-normal heart rate, manageable in most cases but may require dose adjustments.
• Occasional Dizziness or Fatigue: Reported less frequently than with beta-blockers.
• Headaches: Mild to moderate headaches in some patients.

Rare side effects include atrial fibrillation or severe bradycardia, requiring close monitoring in some cases. Patients with sick sinus syndrome or taking CYP3A4 inhibitors should avoid Corlanor.

Cost and Accessibility

One limitation of Corlanor is its high cost in the United States, where a year’s supply can cost up to $4,500. However, patients have explored alternatives like sourcing the medication internationally, where it is often more affordable, or using generic versions.

Conclusion: Is Corlanor Right for You?

Corlanor offers a targeted, promising treatment option for managing POTS symptoms, particularly for patients who have not found relief with traditional medications like beta-blockers. Its selective action on heart rate, minimal side effects, and growing body of evidence make it an appealing option for many.

If you’re considering Corlanor, consult with a healthcare provider experienced in POTS management. They can help determine whether this medication aligns with your treatment goals and develop a personalized plan to address your symptoms effectively. While further research is needed, Corlanor has already improved the lives of many patients, offering hope for those navigating the challenges of POTS.

‍

‍

References:

1. Pollack, A. (2015, April 15). FDA approves Amgen drug to treat heart failure. The New York Times. Retrieved from http://www.nytimes.com/2015/04/16/business/fda-approves-amgen-drug-to-treat-heart-failure.html?_r=0
2. Carroll, J. (2015, April 15). Updated: Amgen wins a much-needed FDA OK—but little respect—for heart drug ivabradine. Fierce Biotech. Retrieved from http://www.fiercebiotech.com/biotech/updated-amgen-wins-a-much-needed-fda-ok-but-little-respect-for-heart-drug-ivabradine
3. Wikipedia. (n.d.). Ivabradine. In Wikipedia. Retrieved November 23, 2024, from http://en.wikipedia.org/wiki/Ivabradine
4. O'Sullivan, J. S., Lyne, A., & Vaughan, C. J. (2021). COVID-19-induced postural orthostatic tachycardia syndrome treated with ivabradine. BMJ Case Reports, 14(6), e243585. doi:10.1136/bcr-2021-243585
5. National Library of Medicine. (n.d.). Study of ivabradine in treatment of chronic heart failure (NCT03182725). ClinicalTrials.gov. Retrieved from http://www.clinicaltrials.gov/study/NCT03182725
6. Sutton, R., Salukhe, T. V., Franzen-McManus, A. C., Collins, A., Lim, P. B., & Francis, D. P. (2014). Ivabradine in treatment of sinus tachycardia mediated vasovagal syncope. Europace, 16(2), 284–288. doi:10.1093/europace/eut226
7. McDonald, C., Frith, J., & Newton, J. L. (2011). Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace, 13(3), 427–430. doi:10.1093/europace/euq390
8. Delle Donne, G., Rosés Noguer, F., Till, J., Salukhe, T., Prasad, S. K., & Daubeney, P. E. F. (2018). Ivabradine in postural orthostatic tachycardia syndrome: Preliminary experience in children. American Journal of Cardiovascular Drugs, 18(1), 59–63. doi:10.1007/s40256-017-0248-x
9. Gee, M. E., Watkins, A. K., Brown, J. N., & Young, E. J. A. (2018). Ivabradine for the treatment of postural orthostatic tachycardia syndrome: A systematic review. American Journal of Cardiovascular Drugs, 18(3), 195–204. doi:10.1007/s40256-017-0252-1
10. Health Rising. (n.d.). Ivabradine for postural orthostatic tachycardia syndrome (POTS). Health Rising. Retrieved November 23, 2024, from http://www.healthrising.org/treating-chronic-fatigue-syndrome/drugs/ivabradine-for-postural-orthostatic-tachycardia-syndrome-pots/
11. Taub, P. R., Zadourian, A., Lo, H. C., Ormiston, C. K., Golshan, S., & Hsu, J. C. (2021). Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. Journal of the American College of Cardiology, 77(7), 861–871. https://doi.org/10.1016/j.jacc.2020.12.029
12. Raj, S. R., & Sheldon, R. S. (2021). Higher-quality evidence to guide our management of postural orthostatic tachycardia syndrome. Heart Rhythm, 18(6), 915–916. https://doi.org/10.1016/j.hrthm.2021.03.005
13. Taub, P. R., Zadourian, A., Lo, H. C., Ormiston, C. K., Golshan, S., & Hsu, J. C. (2021). Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. Journal of the American College of Cardiology, 77(7), 861–871. https://doi.org/10.1016/j.jacc.2020.12.029

‍